These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8073548)

  • 1. Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer.
    Bono AV; Benvenuti C; Damiano G; Lovisolo J
    Urology; 1994 Sep; 44(3):329-34; discussion 334-5. PubMed ID: 8073548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Conservative treatment of high-risk (T1G3) transitional carcinoma].
    Catanzaro F; Torelli F; Catanzaro M; Cappellano F; Pizzoccaro M; Baruffi M; Sironi D; Pozzoli GL
    Arch Ital Urol Androl; 1996 Feb; 68(1):21-4. PubMed ID: 8664915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer.
    Bono AV; Lovisolo JA; Saredi G
    Eur Urol; 2000 Apr; 37(4):478-83. PubMed ID: 10765080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
    Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
    Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; Li ML
    Jpn J Clin Oncol; 2004 Apr; 34(4):202-5. PubMed ID: 15121756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years.
    Patard J; Moudouni S; Saint F; Rioux-Leclercq N; Manunta A; Guy L; Ballanger P; Lanson Y; Hajri M; Irani J; Guillé F; Beurton D; Lobel B;
    Urology; 2001 Oct; 58(4):551-6. PubMed ID: 11597537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.
    Huang B; Zheng J; Yao Z; Fan W; Qiu S; Chen L; Chen J
    World J Urol; 2019 May; 37(5):823-829. PubMed ID: 30191393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
    Rolevich AI; Zhegalik AG; Mokhort AA; Minich AA; Vasilevich VY; Polyakov SL; Krasny SA; Sukonko OG
    World J Urol; 2017 May; 35(5):745-752. PubMed ID: 27604374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours.
    Patard JJ; Rodriguez A; Leray E; Rioux-Leclercq N; Guillé F; Lobel B
    Eur Urol; 2002 Jun; 41(6):635-41; discussion 642. PubMed ID: 12074781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
    Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
    Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin].
    Milonas D; Mickevicius J; Mickevicius R; Motiejūnas A; Sukys D; Gudinaviciene I
    Medicina (Kaunas); 2002; 38 Suppl 1():79-83. PubMed ID: 12556642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.